In Belgium, the availability of Next-Generation Sequencing (NGS) testing is a positive sign, indicating a well-equipped infrastructure and appropriate funding, fostering routine utilization across various healthcare and research domains. However, challenges related to reimbursement and cost constraints loom large, hindering the holistic application of these technologies to benefit all cancer patients.

The analysis emphasizes the need for increased investment in the healthcare system, particularly in reimbursing NGS and liquid biopsy testing, to ensure that these transformative diagnostics are accessible to all in need. This investment is crucial for promoting equity in cancer care and facilitating personalized treatment pathways for patients across Belgium.

Access the detailed insights on Belgium’s molecular diagnostics landscape below.